Table 3.
Analysis of HACA (µg/ml) in high-risk NB patients receiving LTI of ch14.18/CHO.
| P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | P10 | |
|---|---|---|---|---|---|---|---|---|---|---|
| baseline | 0.0 ± 1.0 | 0.0 ± 0.9 | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.1 ± 0.1 | 0.0 ± 0.1 | 0.4 ± 0.6 | 0.0 ± 0.0 | 0.0 ± 0.1 | 0.0 ± 0.1 |
| cycle 2 | 0.0 ± 0.3 | 4.6 ± 0.7 | 11.7 ± 0.5 | 0.4 ± 0.1 | 9.2 ± 1.7 | 0.0 ± 0.0 | 0.0 ± 0.1 | 3.8 ± 0.1 | 0.5 ± 0.0 | 6.7 ± 0.1 |
| cycle 3 | 47.9 ± 5.5 | n. d.* | 7.1 ± 0.3 | 5.6 ± 0.8 | 9.3 ± 2.3 | 29.1 ± 0.9 | 1.1 ± 0.4 | 4.1 ± 0.0 | 11.7 ± 0.7 | 6.2 ± 0.4 |
| cycle 4 | n. d. | n. d. | 26.7 ± 1.1 | 3.9 ± 0.2 | 19.7 ± 0.1 | 0.0 ± 0.2 | 4.4 ± 0.8 | 3.8 ± 0.2 | 24.5 ± 0.3 | n. d. |
| cycle 5 | n. d. | 6.3 ± 1.3 | 59.3 ± 5.4 | 2.8 ± 0.2 | 24.3 ± 0.3 | 0.0 ± 0.1 | 11.5 ± 0.6 | 2.9 ± 0.1 | 23.6 ± 2.2 | 0.7 ± 0.3 |
| Mean | 16.0 | 3.6 | 21.0 | 2.6 | 12.5 | 5.8 | 3.5 | 2.9 | 12.1 | 3.4 |
*
n.d. - not done